Digital Frontiers Health 2022 - day 2 And the LIVE coverage continues as we head into Day Two... This day is set to hold even more points of interest, with the demonstration ‘CX innovation: building experiences that wo
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.